4.6 Article

Maternal antidepressant use and adverse outcomes: a cohort study of 228,876 pregnancies

期刊

出版社

MOSBY-ELSEVIER
DOI: 10.1016/j.ajog.2012.04.028

关键词

adverse outcome; maternal antidepressant; preterm birth

资金

  1. Bristol-Myers Squibb
  2. Eli Lilly and Company
  3. Euthymics Bioscience
  4. Forest Pharmaceuticals
  5. Janssen Pharmaceutica
  6. Novartis Pharmaceuticals
  7. Otsuka Pharmaceuticals
  8. Pamlab
  9. Pfizer
  10. Repligen
  11. St. Jude Medical
  12. Vanderbilt CTSA from the National Institutes of Health [UL1 RR024975-01]
  13. [R03 MH 088902]
  14. [K12 scholar HD 043483]
  15. [1RC4MH092755-01]
  16. [K24 AI 77930]

向作者/读者索取更多资源

OBJECTIVE: The purpose of this study was to describe antidepressant medication use patterns during pregnancy and pregnancy outcomes. STUDY DESIGN: We evaluated a cohort of 228,876 singleton pregnancies that were covered by Tennessee Medicaid, 1995-2007. RESULTS: Of 23,280 pregnant women with antidepressant prescriptions before pregnancy, 75% of them filled none in the second or third trimesters of pregnancy, and 10.7% of them used antidepressants throughout pregnancy. Filling 1, 2, and >= 3 antidepressant prescriptions during the second trimester was associated with shortened gestational age by 1.7 (95% confidence interval [CI], 1.2-2.3), 3.7 (95% CI, 2.8-4.6), and 4.9 (95% CI, 3.9-5.8) days, when controlled for measured confounders. Third-trimester selective serotonin reuptake inhibitor use was associated with infant convulsions; adjusted odds ratios were 1.4 (95% CI, 0.7-2.8); 2.8 (95% CI, 1.9-5.5); and 4.9 (95% CI, 2.6-9.5) for filling 1, 2, and >= 3 prescriptions, respectively. CONCLUSION: Most women discontinue antidepressant medications before or during the first trimester of pregnancy. Second-trimester antidepressant use is associated with preterm birth, and third-trimester selective serotonin reuptake inhibitor use is associated with infant convulsions.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据